Jixia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jixia Wang has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Xinmiao Liang
State Key Laboratory of Phytochemistry and Natural Medicines Dalian Institute of Chemical Physics Chinese Academy of Sciences Dalian China
15 shared publications - Yanfang Liu
Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; Jiangxi Provincial Key Laboratory for Pharmacodynamic Material Basis of Traditional Chinese Medicine, Ganjiang Chinese Medicine Innovation Center, Nanchang, 330000, China
13 shared publications Tao Hou
State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China
12 shared publicationsHan Zhou
State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China
11 shared publicationsFangfang Xu
State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China
9 shared publicationsYanfang Liu
State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China
9 shared publications
Latest Publications
- 29 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-18
Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products
Sphingosine-1-phosphate receptor 1 (S1PR1) belonging to G protein-coupled receptors (GPCRs), plays a significant role in autoimmune diseases and cancer via regulating immune cell migration, vascular barrier function, and cell survival. Although four S1PR1 agonists have been clinically approved, their applications are limited by adverse effects, necessitating the discovery of novel S1PR1 agonists. In this study, we established a HEK293T-hS1PR1 high-throughput screening model for S1PR1 ligand discovery using dynamic mass redistribution (DMR) and fluorescent imaging plate reader (FLIPR) assays. Through structure-based virtual screening of anti-inflammatory compounds, we identified corylin, a natural compound derived from Psoralea corylifolia L., as a novel S1PR1 agonist. Corylin demonstrated micromolar-level agonistic activity with EC50 values of 7.50 μM (95% CI: 6.46–8.75 μM) in DMR assay and 5.99 μM (95% CI: 2.16–16.64 μM) in FLIPR assay. Notably, corylin showed no activity against two other GPCRs (GPR84 and GPR120) commonly co-expressed with S1PR1 in immune cells. Molecular docking indicated that corylin interacted with S1PR1 via hydrophobic interaction, lacking of π-stacking with Trp269, a key interaction for SEW2871. Subsequent 500-ns molecular dynamics simulations revealed a ligand reorientation and the formation of a π-π interaction with Trp269, observed with ~ 50% occupancy, thereby demonstrating the stable binding of corylin to S1PR1. Furthermore, pathway deconvolution analysis confirmed that corylin activated PI3K/Akt and MEK/ERK downstream signaling cascades. This study identifies corylin as a novel S1PR1 agonist with potential for drug design and presents a robust high-throughput screening method for S1PR1 agonist discovery.
- 29 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-18
Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products
Sphingosine-1-phosphate receptor 1 (S1PR1) belonging to G protein-coupled receptors (GPCRs), plays a significant role in autoimmune diseases and cancer via regulating immune cell migration, vascular barrier function, and cell survival. Although four S1PR1 agonists have been clinically approved, their applications are limited by adverse effects, necessitating the discovery of novel S1PR1 agonists. In this study, we established a HEK293T-hS1PR1 high-throughput screening model for S1PR1 ligand discovery using dynamic mass redistribution (DMR) and fluorescent imaging plate reader (FLIPR) assays. Through structure-based virtual screening of anti-inflammatory compounds, we identified corylin, a natural compound derived from Psoralea corylifolia L., as a novel S1PR1 agonist. Corylin demonstrated micromolar-level agonistic activity with EC50 values of 7.50 μM (95% CI: 6.46–8.75 μM) in DMR assay and 5.99 μM (95% CI: 2.16–16.64 μM) in FLIPR assay. Notably, corylin showed no activity against two other GPCRs (GPR84 and GPR120) commonly co-expressed with S1PR1 in immune cells. Molecular docking indicated that corylin interacted with S1PR1 via hydrophobic interaction, lacking of π-stacking with Trp269, a key interaction for SEW2871. Subsequent 500-ns molecular dynamics simulations revealed a ligand reorientation and the formation of a π-π interaction with Trp269, observed with ~ 50% occupancy, thereby demonstrating the stable binding of corylin to S1PR1. Furthermore, pathway deconvolution analysis confirmed that corylin activated PI3K/Akt and MEK/ERK downstream signaling cascades. This study identifies corylin as a novel S1PR1 agonist with potential for drug design and presents a robust high-throughput screening method for S1PR1 agonist discovery.
- 27 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158130
Ellagic acid alleviates ulcerative colitis in a GPR35-dependent manner associated with SDH restoration
- 27 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158130
Ellagic acid alleviates ulcerative colitis in a GPR35-dependent manner associated with SDH restoration
- 22 October 2025
- Published by Wiley in Phytotherapy Research
- Vol. 40 (1) , 21-34
A Natural LDHA Allosteric Inhibitor Geraniin Suppresses Triple‐Negative Breast Cancer Cell Growth
Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with no target, and chemotherapy remains the only treatment in the clinic. Lactate dehydrogenase A (LDHA), a critical enzyme in glycolysis, was reported to be upregulated in TNBC. Only machilin A and berberine were reported as natural LDHA inhibitors with moderate activity at micromolar levels. The aim of this study is to discover novel potent natural LDHA inhibitors, evaluate their anti‐TNBC activity, and explore the mechanisms. LDH activity assay was developed to discover LDHA inhibitors. Biolayer interferometry, molecular docking, and molecular dynamics were applied to explore the mechanisms at the protein level. CCK8, three‐dimensional spheroid formation, wound healing assay, and flow cytometry were applied to detect proliferation, migration, cell cycle, reactive oxygen species, and mitochondrial membrane potential. Quantitative real‐time PCR and western blotting were used for detecting mRNA and protein levels. Five novel nanomolar natural LDHA inhibitors were found. Geraniin exhibited the most potent LDHA inhibition with an IC 50 value of 26.7 ± 7.3 nM. Geraniin showed anti‐TNBC activity both in two‐dimensional and three‐dimensional cell models. Mechanistically, geraniin directly binds to LDHA at the allosteric pocket, downregulates the key enzymes and transcription factors in glycolysis and lipid de novo, arrests the cell cycle in the S phase, suppresses cell migration, raises reactive oxygen species, and disrupts mitochondrial membrane potential. Geraniin was a potent natural LDHA allosteric inhibitor. Geraniin could be a potential candidate for anti‐TNBC treatment.
- 22 October 2025
- Published by Wiley in Phytotherapy Research
- Vol. 40 (1) , 21-34
A Natural LDHA Allosteric Inhibitor Geraniin Suppresses Triple‐Negative Breast Cancer Cell Growth
Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with no target, and chemotherapy remains the only treatment in the clinic. Lactate dehydrogenase A (LDHA), a critical enzyme in glycolysis, was reported to be upregulated in TNBC. Only machilin A and berberine were reported as natural LDHA inhibitors with moderate activity at micromolar levels. The aim of this study is to discover novel potent natural LDHA inhibitors, evaluate their anti‐TNBC activity, and explore the mechanisms. LDH activity assay was developed to discover LDHA inhibitors. Biolayer interferometry, molecular docking, and molecular dynamics were applied to explore the mechanisms at the protein level. CCK8, three‐dimensional spheroid formation, wound healing assay, and flow cytometry were applied to detect proliferation, migration, cell cycle, reactive oxygen species, and mitochondrial membrane potential. Quantitative real‐time PCR and western blotting were used for detecting mRNA and protein levels. Five novel nanomolar natural LDHA inhibitors were found. Geraniin exhibited the most potent LDHA inhibition with an IC 50 value of 26.7 ± 7.3 nM. Geraniin showed anti‐TNBC activity both in two‐dimensional and three‐dimensional cell models. Mechanistically, geraniin directly binds to LDHA at the allosteric pocket, downregulates the key enzymes and transcription factors in glycolysis and lipid de novo, arrests the cell cycle in the S phase, suppresses cell migration, raises reactive oxygen species, and disrupts mitochondrial membrane potential. Geraniin was a potent natural LDHA allosteric inhibitor. Geraniin could be a potential candidate for anti‐TNBC treatment.
- 22 September 2025
- Published by Elsevier in Fitoterapia
- Vol. 187, 106874
Identification of a novel ACLY inhibitor proanthocyanidin B2 from grape seeds with lipid-lowering effect in vitro
- 22 September 2025
- Published by Elsevier in Fitoterapia
- Vol. 187, 106874
Identification of a novel ACLY inhibitor proanthocyanidin B2 from grape seeds with lipid-lowering effect in vitro
- 8 September 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120575
Isobavachalcone ameliorates TNBS-induced Crohn's disease-like colitis via GPR84-PI3K-AKT axis
- 8 September 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120575
Isobavachalcone ameliorates TNBS-induced Crohn's disease-like colitis via GPR84-PI3K-AKT axis
- 18 August 2025
- Published by Elsevier in Fitoterapia
- Vol. 186, 106832
Discovery of dopamine D1 receptor antagonists from Stephania epigaea using label-free cell phenotypic assays
- 18 August 2025
- Published by Elsevier in Fitoterapia
- Vol. 186, 106832
Discovery of dopamine D1 receptor antagonists from Stephania epigaea using label-free cell phenotypic assays
- Open Access
- 18 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2745
Identification of a Novel Antagonist of BRS-3 from Natural Products and Its Protective Effects Against H2O2-Induced Cardiomyocyte Injury
The identification of exogenous ligands from natural products is an alternative strategy to explore the unrevealed physiological functions of orphan G-protein-coupled receptors (GPCRs). In this study, we have successfully identified and pharmacologically characterized licoisoflavone A (LIA) as a novel selective antagonist of BRS-3, an orphan GPCR. Functional studies showed that pretreatment with LIA ameliorated hydrogen peroxide (H2O2)-induced cardiomyocyte injury. Furthermore, LIA pretreatment significantly restored the activities of malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT), as well as lactate dehydrogenase (LDH) levels, in H9c2 cells following H2O2 exposure. The protective effect of LIA was also evident in primary cardiomyocytes from rats and mice against H2O2-induced cell injury but was absent in primary cardiomyocytes derived from bombesin receptor subtype-3 knockout (Brs3−/y) mice, strongly confirming the mechanism of LIA’s action through BRS-3 antagonism. Proteomics studies further revealed that LIA exerted its protective effects via activating the integrin/ILK/AKT and ERK/MAPK signaling pathways. Complementary findings from Bantag-1, a well-recognized antagonist of BRS-3, in human embryonic kidney 293 mBRS-3 (HEK293-mBRS-3) stable cells and B16 cell lines, which demonstrated resistance to H2O2-induced damage, further supported the pivotal role of BRS-3 in oxidative stress-induced cell injury. Our study contributes to expanding our understanding of the potential pharmacological functions of BRS-3, unveiling previously unknown pharmacological functionality of this orphan receptor.
- 18 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2745
Open AccessIdentification of a Novel Antagonist of BRS-3 from Natural Products and Its Protective Effects Against H2O2-Induced Cardiomyocyte Injury
The identification of exogenous ligands from natural products is an alternative strategy to explore the unrevealed physiological functions of orphan G-protein-coupled receptors (GPCRs). In this study, we have successfully identified and pharmacologically characterized licoisoflavone A (LIA) as a novel selective antagonist of BRS-3, an orphan GPCR. Functional studies showed that pretreatment with LIA ameliorated hydrogen peroxide (H2O2)-induced cardiomyocyte injury. Furthermore, LIA pretreatment significantly restored the activities of malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT), as well as lactate dehydrogenase (LDH) levels, in H9c2 cells following H2O2 exposure. The protective effect of LIA was also evident in primary cardiomyocytes from rats and mice against H2O2-induced cell injury but was absent in primary cardiomyocytes derived from bombesin receptor subtype-3 knockout (Brs3−/y) mice, strongly confirming the mechanism of LIA’s action through BRS-3 antagonism. Proteomics studies further revealed that LIA exerted its protective effects via activating the integrin/ILK/AKT and ERK/MAPK signaling pathways. Complementary findings from Bantag-1, a well-recognized antagonist of BRS-3, in human embryonic kidney 293 mBRS-3 (HEK293-mBRS-3) stable cells and B16 cell lines, which demonstrated resistance to H2O2-induced damage, further supported the pivotal role of BRS-3 in oxidative stress-induced cell injury. Our study contributes to expanding our understanding of the potential pharmacological functions of BRS-3, unveiling previously unknown pharmacological functionality of this orphan receptor.
- 17 March 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (13) , 2740-2748
Bioactivity-guided isolation of anti-proliferative compounds from Curcuma zedoaria against triple negative breast cancer cells
Triple-negative breast cancer (TNBC) presents limited clinically effective treatment options. Curcuma zedoaria (C. zedoaria), a traditional medicine, has been used in China to treat various cancers including TNBC, although its active components remain unclear. Herein, we applied multidimensional liquid chromatography combined with bioactivity assay to discover anti-proliferative compounds against TNBC cells from C. zedoaria. Initially, 26 fractions were generated through first-dimensional reverse-phase liquid chromatography and profiled using SUM159 cells for its anti-proliferative activity. Two active fractions were identified and separated. Following the third-dimensional separation, we successfully isolated two compounds, diarylheptanoid a and diarylheptanoid b, and found that both compounds displayed moderate potency in inhibiting SUM159 proliferation with IC50 values of 19.82 ± 3.08 μM and 28.16 ± 1.97 μM, respectively. Transcriptome analysis revealed that the differentially expressed genes induced by diarylheptanoid a were mainly concentrated with the actin function and involved in motor protein pathways. This study suggests that diarylheptanoids may contribute to the anti-TNBC effects of C. zedoaria and provide potential scaffolds for anti-TNBC drug development.
- 17 March 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (13) , 2740-2748
Bioactivity-guided isolation of anti-proliferative compounds from Curcuma zedoaria against triple negative breast cancer cells
Triple-negative breast cancer (TNBC) presents limited clinically effective treatment options. Curcuma zedoaria (C. zedoaria), a traditional medicine, has been used in China to treat various cancers including TNBC, although its active components remain unclear. Herein, we applied multidimensional liquid chromatography combined with bioactivity assay to discover anti-proliferative compounds against TNBC cells from C. zedoaria. Initially, 26 fractions were generated through first-dimensional reverse-phase liquid chromatography and profiled using SUM159 cells for its anti-proliferative activity. Two active fractions were identified and separated. Following the third-dimensional separation, we successfully isolated two compounds, diarylheptanoid a and diarylheptanoid b, and found that both compounds displayed moderate potency in inhibiting SUM159 proliferation with IC50 values of 19.82 ± 3.08 μM and 28.16 ± 1.97 μM, respectively. Transcriptome analysis revealed that the differentially expressed genes induced by diarylheptanoid a were mainly concentrated with the actin function and involved in motor protein pathways. This study suggests that diarylheptanoids may contribute to the anti-TNBC effects of C. zedoaria and provide potential scaffolds for anti-TNBC drug development.
- 6 March 2025
- Published by Elsevier in Phytomedicine
- Vol. 140, 156618
Bakuchiol mitigates colitis through GPR120 activation
- 6 March 2025
- Published by Elsevier in Phytomedicine
- Vol. 140, 156618
Bakuchiol mitigates colitis through GPR120 activation